Abstract
SummaryDevelopments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients.
Highlights
Adjuvant endocrine therapy is a milestone of treatment in hormone-receptor positive early breast cancer
The disease-free survival (DFS) and overall survival (OS) in the group of patients with an extended adjuvant aromatase inhibitor (AI) therapy of 5 years was not significantly better than in the group with AI extension of 2.5 years, and this study showed no benefit of AI-based adjuvant therapy longer than a maximum of 7.5 years
The NSABP B-52 trial evaluated pathologic complete response rates in patients with hormone receptor and HER2-positive breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without concurrent estrogen deprivation therapy
Summary
Received: 6 February 2017 / Accepted: 28 March 2017 / Published online: 25 April 2017. Summary Developments in early breast cancer presented at the 2016 San Antonio Breast Cancer Symposium included important studies on extending adjuvant endocrine therapy with aromatase inhibitors, the role of bisphosphonates, and evidence for molecular prognostic factors and circulating tumor cells in early stage breast cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
